NCT06356272 - Oropharynx (OPX) Biomarker Trial | Biotech Hunter

Enrollment

700

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

November 30, 2029

Study Completion Date

November 30, 2029

Conditions

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Metastatic Oropharyngeal Squamous Cell CarcinomaOropharyngeal Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaStage III Oropharyngeal (p16-Negative) Carcinoma AJCC V8Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC V8Head and Neck CarcinomaHead and Neck NeoplasmSalivary Gland NeoplasmsThyroid Gland Neoplasm

Interventions

OTHER

Non-Interventional Study

Non-interventional study

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester